Leerink Partnrs Reiterates Outperform Rating for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA)‘s stock had its “outperform” rating reiterated by stock analysts at Leerink Partnrs in a report issued on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for XOMA’s Q1 2024 earnings at ($0.85) EPS, Q2 2024 earnings at ($0.79) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.69) EPS, FY2024 earnings at ($2.87) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $3.31 EPS.

Other analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $74.00 target price on shares of XOMA in a research report on Wednesday. SVB Leerink assumed coverage on shares of XOMA in a research report on Monday. They issued an “outperform” rating and a $40.00 target price on the stock.

XOMA Stock Up 1.9 %

Shares of XOMA stock opened at $25.82 on Monday. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34. The company’s fifty day simple moving average is $25.06 and its two-hundred day simple moving average is $20.68. The company has a market cap of $300.54 million, a P/E ratio of -6.39 and a beta of 0.57. XOMA has a 12-month low of $13.48 and a 12-month high of $27.00.

XOMA (NASDAQ:XOMA) last announced its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The business had revenue of $1.83 million for the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. Research analysts anticipate that XOMA will post -1.73 EPS for the current year.

Institutional Trading of XOMA

A hedge fund recently raised its stake in XOMA stock. BNP Paribas Financial Markets boosted its position in shares of XOMA Co. (NASDAQ:XOMA) by 55.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 3,543 shares of the biotechnology company’s stock after purchasing an additional 1,266 shares during the quarter. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.